690 related articles for article (PubMed ID: 21459216)
1. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Ciulla T; Boyer D; Holz FG; Tolentino M; Gupta A; Duarte L; Madreperla S; Gonder J; Kapik B; Billman K; Kane FE;
Ophthalmology; 2011 Apr; 118(4):626-635.e2. PubMed ID: 21459216
[TBL] [Abstract][Full Text] [Related]
2. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
[TBL] [Abstract][Full Text] [Related]
3. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
[TBL] [Abstract][Full Text] [Related]
4. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
Campochiaro PA; Hafiz G; Shah SM; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane F;
Ophthalmology; 2010 Jul; 117(7):1393-9.e3. PubMed ID: 20202684
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results.
Jain N; Stinnett SS; Jaffe GJ
Ophthalmology; 2012 Jan; 119(1):132-7. PubMed ID: 21924503
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial.
Gillies MC; McAllister IL; Zhu M; Wong W; Louis D; Arnold JJ; Wong TY
Ophthalmology; 2011 May; 118(5):866-72. PubMed ID: 21232801
[TBL] [Abstract][Full Text] [Related]
8. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
[TBL] [Abstract][Full Text] [Related]
9. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
Cunha-Vaz J; Ashton P; Iezzi R; Campochiaro P; Dugel PU; Holz FG; Weber M; Danis RP; Kuppermann BD; Bailey C; Billman K; Kapik B; Kane F; Green K;
Ophthalmology; 2014 Oct; 121(10):1892-903. PubMed ID: 24935282
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema: a microperimetry and optical coherence tomography study.
Grenga P; Lupo S; Domanico D; Vingolo EM
Retina; 2008 Oct; 28(9):1270-5. PubMed ID: 18664938
[TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone for diabetic macular edema.
Gibran SK; Khan K; Jungkim S; Cleary PE
Ophthalmology; 2007 May; 114(5):890-4. PubMed ID: 17467527
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M
Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial.
Bonini-Filho MA; Jorge R; Barbosa JC; Calucci D; Cardillo JA; Costa RA
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3845-9. PubMed ID: 16186372
[TBL] [Abstract][Full Text] [Related]
14. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema.
Sivaprasad S; Ockrim Z; Massaoutis P; Ikeji F; Hykin PG; Gregor ZJ
Retina; 2008; 28(10):1435-42. PubMed ID: 18628722
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.
Sutter FK; Simpson JM; Gillies MC
Ophthalmology; 2004 Nov; 111(11):2044-9. PubMed ID: 15522370
[TBL] [Abstract][Full Text] [Related]
17. Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up.
Veritti D; Lanzetta P; Perissin L; Bandello F
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2391-7. PubMed ID: 19117937
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial.
Audren F; Erginay A; Haouchine B; Benosman R; Conrath J; Bergmann JF; Gaudric A; Massin P
Acta Ophthalmol Scand; 2006 Oct; 84(5):624-30. PubMed ID: 16965492
[TBL] [Abstract][Full Text] [Related]
19. Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema.
Ozdemir H; Karacorlu M; Karacorlu SA
Am J Ophthalmol; 2005 Aug; 140(2):251-5. PubMed ID: 15992756
[TBL] [Abstract][Full Text] [Related]
20. Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema.
Er H
Am J Ophthalmol; 2008 Aug; 146(2):332-3; author reply 333. PubMed ID: 18656589
[No Abstract] [Full Text] [Related]
[Next] [New Search]
